In recent years, immune checkpoint inhibitors have transformed cancer treatment by harnessing the body’s own immune system to attack tumors. These therapies, which target proteins such as PD-1, can produce long-lasting remissions in some patients with advanced cancers like melanoma and non-small cell lung cancer. However, not all patients respond, and researchers have been searching for factors that influence treatment success.
A new study has uncovered an unexpected dietary link. Sucralose, a widely used zero-calorie sweetener found in many diet sodas, protein powders, and sugar-free snacks, may reduce the effectiveness of immunotherapy. The research, conducted in both cancer patients and mouse models, found that higher sucralose intake before or during treatment was associated with poorer outcomes.
The key appears to be the gut microbiome, the community of bacteria and other microorganisms living in the digestive tract. The study showed that sucralose consumption altered the balance of gut microbes, leading to a decrease in beneficial bacterial diversity and an increase in certain bacteria that degrade the amino acid arginine. Arginine is essential for optimal T cell function, and its depletion was linked to signs of T cell exhaustion, a state in which immune cells lose their ability to attack cancer effectively.
In mouse experiments, sucralose consumption not only changed the microbiome but also impaired the ability of immune cells to infiltrate tumors and kill cancer cells. When researchers restored arginine levels through supplementation or transplanted gut bacteria from mice that responded well to therapy, the animals regained their ability to respond to treatment.
The findings suggest that sucralose is not biologically inert and may have unintended consequences for people undergoing cancer immunotherapy. While more research is needed to confirm these effects in larger human studies, the results highlight the importance of diet and gut health in cancer treatment. Patients who are considering or receiving immunotherapy should discuss their use of artificial sweeteners with their healthcare team.
